15.81
+3.13%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Mineralys Therapeutics
From its filings with the US Securities and Exchange Commission
Mineralys Therapeutics is based in Radnor, Pennsylvania. Its shares trade on Nasdaq under the ticker MLYS. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $154.7m. At that date it held total assets of $661.8m and shareholders' equity of $646.7m.
We are a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. Our product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that we are developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities such as chronic kidney disease (CKD) and obstructive sleep apnea (OSA).
In the United States, there are approximately 120 million patients with sustained elevated blood pressure (BP), or hypertension. Approximately 60 million patients are treated and over 30 million do not achieve their BP goal, with approximately 20 million having systolic BP levels greater than 140 mmHg. Patients with hypertension that persists despite taking two or more medications have 1.8 and 2.5 times greater mortality risk due to either cardiovascular disease or stroke, respectively. Dysregulated aldosterone levels are a key factor in uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) in approximately 30% of patients.
Quoted from its 10-K, filed 12 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 10 Feb 2023
- Employees
- 76
- Website
- mineralystx.com ↗
- Head office
- 150 N. RADNOR CHESTER ROAD, RADNOR, PA
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. Glenn SblendorioNon-Executive Independent Chairman of the Board$251,888
- Mr. Jon CongletonChief Executive Officer, Director, since 2020$5.4m
- Dr. Brian SlingsbyFounder, Independent Director, since 2019$275,314
- Mr. Adam LevyChief Financial Officer, Company Secretary$2.8m
- Dr. David RodmanChief Medical Officer$2.9m
- Dr. Srinivas AkkarajuIndependent Director$246,314
- Dr. Derek DiroccoIndependent Director$249,814
- Mr. Alexander M. GoldIndependent Director$434,582
- Ms. Daphne KarydasIndependent Director$252,314
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 39
- Environment
- 39
- Social
- 67
- Governance
- 12
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Mineralys Therapeutics focuses on lorundrostat, a selective aldosterone synthase inhibitor for hypertension treatment.
- The company completed the Target-HTN Phase II trial for lorundrostat in uncontrolled hypertension patients.
- Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2 enzyme production.
Weaknesses
- Mineralys Therapeutics has only 76 employees, a small team for a clinical-stage biopharmaceutical company.
- The company's sole focus on lorundrostat limits diversification in its product pipeline.
- Radnor, Pennsylvania headquarters may restrict access to broader biotech talent pools.
Opportunities
- Expanding lorundrostat use to chronic kidney disease (CKD) treatment offers new market potential.
- The Target-HTN trial success could attract additional investment for further development.
- Growing hypertension prevalence in the US provides a large patient population for lorundrostat.
Threats
- Competition from other aldosterone-targeting therapies could reduce market share.
- Regulatory approval delays for lorundrostat may impact commercialization timeline.
- High development costs for biopharmaceuticals could strain financial resources.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.